Janet Hammond, MD, PhD, is a distinguished medical professional and researcher who currently holds the position of Chief Development Officer at Atea Pharmaceuticals Inc. Dr. Hammond's career is marked by a strong commitment to advancing medical science and improving patient outcomes. She earned her MD from Harvard Medical School and her PhD in Molecular Biology from the Massachusetts Institute of Technology (MIT), showcasing her deep expertise in both clinical medicine and foundational research. Throughout her career, Dr. Hammond has made significant contributions to the field of infectious diseases and antiviral drug development. Before joining Atea Pharmaceuticals, she held key leadership roles at several prominent biotech and pharmaceutical companies, where she spearheaded numerous clinical trials and research initiatives that led to the development of groundbreaking therapies. Her work has been published in numerous peer-reviewed journals, and she has received several accolades for her contributions to medical science. As Chief Development Officer at Atea Pharmaceuticals, Dr. Hammond plays a pivotal role in overseeing the company's research and development efforts, particularly in the area of antiviral treatments. Her strategic vision and leadership have been instrumental in advancing Atea's pipeline of innovative therapies. Under her guidance, the company has made significant strides in developing treatments for viral infections, positioning Atea as a leader in the field. Dr. Hammond's expertise and dedication continue to drive the company's mission to address unmet medical needs and improve global health.